Breaking
•California charity walk raises record $3.3m for children with special needs•North Dakota mother denied father access; court awards him 19 extra weekends•On Diwali, why worry about bad air, it'll improve on own: Yogi Adityanath•Another Big Market Team Joins Chase for Tarik Skubal - Yahoo Sports•Can a $700 Million Contract Guarantee a World Series Championship? - Yahoo Sports•At MLB GM Meetings, the Phillies are at a crossroads while the Mets have a clear priority - CBS Sports•GB and Wales' Griffiths banned after drug test - Yahoo Sports•Formula 1 Season To End In Middle East Despite Tensions - TheLines.com•U.S. military faces new security concerns in Europe - Twin States News•Study Suggests Not All Obesity Means Ill-Health - U.S. News & World Report•Bengals' Zac Taylor apologizes for failed trade with Eagles: 'It was on our end' - ESPN•FKA Twigs Becomes Josephine Baker in First Look at Maïmouna Doucouré’s Buzzy Biopic•STAT+: Most-favored nations policy makes drugmakers rethink launches abroad•New OPT fee could drive int'l students away, US universities warn Trump admin•Breaking Down How Oklahoma's Offense Changed in Game 1 Under Jason Witten - Sports Illustrated•Texas football vs LSU: Breaking down the challenge posed to each offense by two elite pass rushes - 247Sports•Holiday Budgets Shrink: How to Celebrate Without Breaking the Bank - KITV•After 3 Elite Eight losses, Tennessee basketball sets sights on breaking through to Final Four - The Daily Beacon•AMA adopts new policies on final day of Interim Meeting - American Medical Association | AMA•Turkey's president calls Gaza war an 'ecocide' at UN climate summit; Israel: 'Campaign of lies' - The Times of Israel•California charity walk raises record $3.3m for children with special needs•North Dakota mother denied father access; court awards him 19 extra weekends•On Diwali, why worry about bad air, it'll improve on own: Yogi Adityanath•Another Big Market Team Joins Chase for Tarik Skubal - Yahoo Sports•Can a $700 Million Contract Guarantee a World Series Championship? - Yahoo Sports•At MLB GM Meetings, the Phillies are at a crossroads while the Mets have a clear priority - CBS Sports•GB and Wales' Griffiths banned after drug test - Yahoo Sports•Formula 1 Season To End In Middle East Despite Tensions - TheLines.com•U.S. military faces new security concerns in Europe - Twin States News•Study Suggests Not All Obesity Means Ill-Health - U.S. News & World Report•Bengals' Zac Taylor apologizes for failed trade with Eagles: 'It was on our end' - ESPN•FKA Twigs Becomes Josephine Baker in First Look at Maïmouna Doucouré’s Buzzy Biopic•STAT+: Most-favored nations policy makes drugmakers rethink launches abroad•New OPT fee could drive int'l students away, US universities warn Trump admin•Breaking Down How Oklahoma's Offense Changed in Game 1 Under Jason Witten - Sports Illustrated•Texas football vs LSU: Breaking down the challenge posed to each offense by two elite pass rushes - 247Sports•Holiday Budgets Shrink: How to Celebrate Without Breaking the Bank - KITV•After 3 Elite Eight losses, Tennessee basketball sets sights on breaking through to Final Four - The Daily Beacon•AMA adopts new policies on final day of Interim Meeting - American Medical Association | AMA•Turkey's president calls Gaza war an 'ecocide' at UN climate summit; Israel: 'Campaign of lies' - The Times of Israel
TheNewsPulse.pro
Home/clinical trials/diseases/drugs
clinical_trials

Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

Confidence86·multiple reportsImportance88NP-EVT-20261111-E020C71

(MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...

Read the original at the primary source
Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint
11/11/2026, 6:07:05 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse

Discussion

ChatsPulse · 0 threads

No discussion yet. Sign in and start the first thread —